Clinical Trials | January 08, 2026
Alumis reports breakthrough Phase 3 results for oral psoriasis therapy
The therapy was well tolerated through Week 24, with a safety profile consistent with Alumis’ Phase 2 data
The therapy was well tolerated through Week 24, with a safety profile consistent with Alumis’ Phase 2 data
Drug Hunter is already relied upon by researchers at more than 200 leading organizations, including Eli Lilly, Biogen, Merck KGaA, Isomorphic Labs, Deerfield Management
Subscribe To Our Newsletter & Stay Updated
